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The interleukin-10 promoter genotype determines clinical im- such as interleukin (IL)-6 or tumor necrosis factor-
mune function in hemodialysis patients. (TNF-) by leukocytes [1] and elevated levels of acute
Background. Immune dysfunction and the impaired hepati- phase proteins, such as C reactive protein (CRP) [2], aretis B vaccination response are complications of chronic renal
markers of this inflammation. The immune system infailure that are tightly associated with inflammation induced
by uremia and blood-membrane contacts. Proinflammatory cy- hemodialysis patients is further characterized by a defi-
tokines, such as interleukin (IL)-6, are counter-regulated by cient effector function toward bacterial and viral infec-
IL-10 with a large interindividual variability. Part of the vari- tions, which are responsible for up to 15% of the mortal-ability of cytokine production is genetically determined since
ity in this population [3]. In addition, vaccinations arepolymorphisms in the cytokine gene promoters lead to high
or low production. The aim of this study was to detect the largely unsuccessful in this patient group [4–6]. This is in
genetic influence of the IL-10 promoter on immune function part due to an impaired costimulatory signaling of antigen
of chronic hemodialysis patients. presenting cells toward T-lymphocytes [7]. Moreover, a
Methods. The IL-10 genotype (polymorphic bases at posi-
correlation between the inflammatory activation and im-tions1082 and819) was determined in 272 chronic hemodi-
mune function also has been shown [1]. The highest pro-alysis patients using highly specific PCR and related to the
patients’ response to a triple vaccination against hepatitis B. duction of proinflammatory cytokines by leukocytes is
Secretion of IL-10 and IL-6 by peripheral blood leucocytes in associated with a heavily impaired function of the immune
vitro was determined by ELISA.
system that becomes clinically apparent as a non-responseResults. The prevalence of the IL-10 genotypes in dialysis
toward a standardized protocol of hepatitis B vaccination.patients with well-preserved immune function (vaccination re-
sponders) was similar to the general population. In contrast, In contrast, dialysis patients with a better preserved im-
prevalence of the1082G* allele (associated with high produc- mune function (hepatitis B vaccine responders) have only
tion of IL-10) was low in the nonresponders. The relative risk slightly elevated levels of inflammatory cytokines such asof vaccination nonresponse in patients homozygous for the
IL-6 that are clearly lower than in the nonresponder group.1082A* allele was 1.394 (95% CI, 1.091 to 1.781, P  0.05)
compared to those homozygous for 1082G*. There was no During recent years the causes of inflammation in dial-
relationship between the IL-10 genotype and the type of renal ysis patients have been studied extensively. Among them,
disease. uremia itself is the most prominent factor that influences
Conclusions. The IL-10 genotype determines IL-10 produc-
immune competent cells by retention of many substancestion in dialysis patients, which down-regulates uremia- and
that may alter their cytokine profile [8]. Furthermore,dialysis-induced chronic inflammation and helps to preserve
immune defense functions. the dialysis procedure leads to repetitive activation of the
complement system [9, 10], thereby inducing cytokine
production in monocytes [11]. Unless purified dialysate
Uremia and hemodialysis are known to induce chronic is used, the passage of monocyte activating endotoxins
systemic inflammation in patients with end-stage renal through the dialyzer membrane from the dialysate com-
disease. Enhanced production of inflammatory cytokines partment to the blood side also may occur [12]. Although
the reasons for inflammation are known, there has been
a lack of explanation for the large interindividual differ-Key words: cellular immunity, kidney failure, dialysis, monocyte physi-
ology, polymorphism, single nucleotide, hepatitis B, inflammation. ences in how patients cope with inflammation-inducing
influences. In particular, it is largely unknown why one
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Table 1. Interleukin-10 (IL-10) promoter polymorphic allelepatibility are no longer that large [13] and the interindi-
frequencies in hemodialysis patients grouped according to their
vidual variation is independent of the dialyzer material. response to a hepatitis B vaccination (responder, 164 patients;
nonresponder, 108 patients)The immune system has a physiologic mechanism to
limit and shut down inflammatory responses after they Allele Responder Nonresponder P
have been successful in the defense against pathogens.
1082
With a latency of 8 to 12 hours, the initial secretion of G 153 (46.6%) 75 (34.7%) 0.006
A 175 (53.4%) 141 (65.3%)IL-6 and TNF- is followed by the cytokine IL-10, which
819down-regulates the secretion of all proinflammatory fac-
C 246 (75.0%) 143 (66.2%) 0.033
tors in monocytes and lymphocytes [14]. Our earlier T 82 (25.0%) 73 (33.8%)
study showed that the levels of IL-10 produced by mono- IL-10 promoter polymorphisms were detected at positions 1082 and 819
upstream of the coding sequence. At position 1082 bases G or A are observedcytes of dialysis patients are inversely correlated with
while at position 819 C or T occurs.their production of IL-6. In addition, IL-10 levels are
higher in hepatitis B vaccine responders than non-
responders [1]. Part of the high interindividual variation
in the amount of IL-10 produced upon a certain stimulus IL-10 promoter genotyping
is genetically determined. Polymorphisms in the pro-
DNA was extracted from 500 L of venous blood anti-moter of the IL-10 gene influence the quantity of the
coagulated with ethylenediaminetetraacetic acid (EDTA).cytokines’ secretion [15]. Given large interindividual dif-
The cells were lysed by incubation with proteinase Kferences in both immune defense function and inflam-
(Sigma Chemicals, Deisenhofen, Germany) for 10 min-matory activation, we studied the IL-10 genotype in he-
utes at 56C. Further preparation was done using themodialysis patients to find out whether this genetic factor
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Ger-contributes to the severity of the uremic immune defect.
many) according to the manufacturer’s protocol.
The DNA was analyzed by highly specific ARMS-
METHODS PCR (amplification refractory mutation system [16]).
This protocol is based on a polymerase chain reactionPatients
(PCR) using primers ending 3 with the complementaryThis study included 272 chronic hemodialysis patients
base for the single polymorphic base in the promoterfrom six German dialysis centers. All patients were on
sequence. Stringency of reaction parameters assures thatthrice weekly treatment for at least three months. Pa-
a PCR product is only formed when the 3 base matches.tients with evidence of a malignant tumor, an active
We used a Hybaid PCR Express thermocycler (Hybaidvasculitis or systemic disease such as systemic lupus ery-
Ltd, Teddington, UK) and the Perkin Elmer AmpliTaqthematosus, ongoing immunosuppressive therapy, or pa-
Gold Polymerase (Applied Biosystems, Weiterstadt, Ger-tients testing positive for hepatitis B antigen (HbsAg)
many). Each 50 L reaction contained 5 L DNA-solu-were excluded. There were no exclusions regarding he-
tion, 1 U Taq polymerase, 5 L 10  buffer, 3.5 mmol/Lmodialysis treatment modalities (duration, dialysis dose,
MgCl2, 400 mol/L dATP, dGTP, dCTP and dTTP, andtype of membrane) or the type of renal disease except
0.2 mol/L of both primers. To achieve the high specific-those stated above. All patients had received at least three
ity the following cycler program was used: activation ofintramuscular injections of a recombinant hepatitis B
polymerase 95C for seven minutes, thereafter 30 cyclesvaccine (Engerix B, Smith Kline Beecham, Munich, Ger-
at 95C for one minute denaturation, 64C for 1.45 min-many; or Gen H-B-Vax, Pasteur Me´rieux, Leimen, Ger-
utes of annealing and elongation, and finally, once atmany) at months 0, 1 and 6 before entry to this study.
72C for a ten minute elongation. Each genotyping wasThe vaccination result was determined between months
done by five reactions: -actin as an internal control (6617 and 12 by the detection of anti-HBs antibodies. Patients
bp product length), and two reactions for both polymor-with anti-HBs 	10 IU/mL at this time were termed “re-
phic bases at positions 1082 (258 bp product length)sponders” while patients with anti-HBs10 IU/mL were
and819 (233 bp product length). The primer sequencestermed “nonresponders.” Production of antibodies fol-
for -actin were: sense, TGA CGG GGT CAC CCA CAClowing additional vaccinations later on was not evaluated
TGT GCC; antisense, CTA GAA GCA TTT GCG GTGfor this study. Responders and nonresponders of this
GAC GAT G. Primer sequences for the IL-10 polymor-study did not differ in the average dose of erythropoietin
phisms were used as published previously [16, 17]. PCR-(responder, 4719 
 4252 IU/week; nonresponders,
based typing was controlled by direct sequencing of the4277 
 4462 IU/week), the parathormone (responder,
promoter region starting from positions 1103 to 886224 
 262 pg/mL; nonresponder 260 
 292 pg/mL) or
as well as from positions 857 to 537 in eight casesthe application of vitamin D preparations (responder,
(SEQLAB, Go¨ttingen, Germany).52% of patients; nonresponder, 46% of patients). All
patients gave informed consent. The PCR product was visualized by gel electrophoresis
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Table 3. Prevalence of the entire IL-10 genotype in hemodialysisTable 2. Relative risk of nonresponse to hepatitis B vaccination in
patients homozygous or heterozygous for the –1082 allele or the patients grouped according to the vaccination response
against hepatitis B–819 allele of the IL-10 promoter
Relative 95% confidence Genotype Responder Nonresponder Phenotype
Allele risk interval P
ATA-ATA 10 (6.1%) 14 (13.0%) Low IL-10
ACC-ACC 16 (9.8%) 9 (8.3%) Low IL-10Homozygous 1082 G* 1
Heterozygous 1082 1.175 0.941–1.459 0.177 ACC-ATA 27 (16.5%) 26 (24.1%) Low IL-10
GCC-ACC 34 (20.7%) 24 (22.2%) Intermediate IL-10Homozygous 1082 A* 1.394 1.091–1.781 0.012
Homozygous 819 C* 1 GCC-ATA 35 (21.3%) 19 (17.6%) Intermediate IL-10
GCC-GCC 42 (25.6%) 16 (14.8%) High IL-10Heterozygous –819 1.126 0.920–1.377 0.291
Homozygous 819 T* 1.566 0.961–2.553 0.040 The three characters give the bases at positions 1082, 819 and 592 of
the IL-10 promoter haplotype. The genotype column shows the two haplotypes
using a six-character code. Position 592 of the IL-10 promoter is coupled to
819 and was therefore not genotyped separately. The Table gives the number
of patients and the prevalence (%) of the genotype in each response group.on a 1.5% agarose gel stained with ethidium bromide There were no statistically significant differences due to the high number of
groups for this analysis. The phenotype column groups the genotypes accordingby an electronic documentation system (Kodak EDAS
to the levels of the IL-10 protein that have been found [15].120/1D Image Analysis Software; Life Technologies,
Karlsruhe, Germany).
Cell culture and cytokine measurements
eter to stratify hemodialysis patients with regard to the
Heparinized blood samples were drawn from 28 hemo-
severity of their immune defect. We tested the frequen-dialysis patients from one dialysis center, among them
cies of IL-10 alleles in dialysis patients grouped into15 homozygous for 1082 G* and 13 homozygous for
responders or nonresponders to this previously applied1082 A*. The patients from the two genotype groups
vaccination. The analysis comprised 164 responders anddid not differ with regard to the average dose of erythro-
108 nonresponders; thus there were slightly more non-poietin, the parathormone, the dialysis quality (Kt/V) or
responders in the study group than would be expectedthe choice of membrane. All samples were drawn prior
in a prospective vaccination study. The percentage ofto a hemodialysis session. Peripheral blood mononuclear
responders varied between the different centers with acells (PBMC) were prepared by centrifugation of blood
range from 57% to 68% without statistically significanton a Ficoll gradient (  1.077; Linaris, Bettingen, Ger-
differences. Table 1 shows the frequencies of the poly-many). Cells were adjusted to 1  106/mL in RPMI 1640
morphic bases at positions 1082 and 819 in the IL-10(Biochrom, Berlin, Germany) supplemented with 5% fe-
promoter upstream of the coding sequence. The preva-tal calf serum, 2 mmol/L glutamin, 100 U/mL penicillin,
lence of1082 G* was clearly lower in the nonresponderand 10g/mL streptomycin. Cultures were performed with
group, as was the prevalence of the 819 C* comparedor without lipopolysaccharide (LPS; E. coli 100 ng/mL;
to the responder group. The polymorphic base at 592Sigma Chemicals), PHA (PHA-L 62.5 ng/mL; Biochrom),
or anti-CD3 (OKT-3 10 ng/mL; Janssen-Cilag, Neuss, was not determined separately, since592 C* is coupled
Germany) for 24 hours. Thereafter, culture supernatants to 819 C* and 592 A* is coupled to 819 T* [15, 18].
were frozen until cytokine detection was performed. This Table 2 analyzes the relative risks of nonresponse of
was done by a commercially available sandwich enzyme- patients homozygous or heterozygous for a 1082 or a
linked immunosorbent assay (ELISA) system for IL-6 819 allele.
or IL-10 (Pharmingen, Hamburg, Germany). Table 3 presents the entire IL-10 genotypes of the
patients in relation to the vaccination response. ThereStatistics
was a tendency toward a lower prevalence of the homo-
For data management and statistical analysis we used zygous GCC-GCC genotype in nonresponder patients
the Prism V3.02 statistical software (Graphpad, San than in the responder group; however, this did not reach
Diego, USA). Allelic frequencies were compared by statistical significance due to the high number of geno-
Fisher’s exact test. Gender distribution was compared type groups. In addition, the prevalence of the homozy-
by the chi-square test, mean age in the different genotype gous ATA-ATA genotype tended to be higher in non-
groups was compared by the Kruskal-Wallis test. Cyto-
responder patients. However, this genotype was rarelykine protein data were compared by the Mann-Whitney
observed in all patients (Table 3).U test. Results were estimated significant at P  0.05.
There was no difference in age or gender between
patients with different IL-10 genotypes, which might
RESULTS have biased the results (data not shown). Similarly, the
Relationship between the IL-10 genotype and causes of end-stage renal failure did not differ in the
immune function frequencies of the IL-10 promoter genotypes (Table 4)
excluding further possible confounding factors. In addi-Immune response to a standardized triple injection of
recombinant hepatitis B vaccine is an established param- tion, there was no difference in the genotype distribution
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Table 4. Prevalence of IL-10 genotypes in patients with 19–21]. There are multiple causes for this cytokine activa-
different renal diseases
tion that establishes a state of chronic inflammation.
Diabetic Glomerulo- Interstitial Polycystic Others/ Many immunoactive proteins are metabolized by the
Genotype nephropathy nephritis diseases disease uncertain kidneys and renal failure leads to elevated plasma levels
ACC-ACC 4 8 3 2 8 of molecules that influence leucocyte function. In addi-
ACC-ATA 15 12 6 5 15
tion, contact between blood and the artificial surfaces ofATA-ATA 6 5 2 3 8
GCC-ACC 10 16 6 6 20 the dialyzers induces complement activation that con-
GCC-ATA 16 11 5 5 17 tributes to cytokine induction in monocytes [11, 22]. Fur-
GCC-GCC 11 17 6 8 16
thermore, endotoxins and fragments thereof may pass
Total 62 69 28 29 84 certain types of dialyzer membranes from contaminated
There were no statistically significant differences in the prevalence of the geno- dialysate to the blood compartment [12].types among patients with different renal diseases.
Chronic inflammation in dialysis patients is associated
with many complications such as immune dysfunction,
amyloidosis, malnutrition, anemia and probably progres-
sive atherosclerosis. When the immune response to hepa-between the different treatment centers (data not shown).
A subgroup analysis revealed that the tendency toward titis B vaccination is used as an in vivo parameter for
the extent of the immune defect in hemodialysis patients,a higher prevalence of the IL-10 low producer genotypes
in nonresponders was present both in diabetics and non- those with the most severely impaired defense functions
(hepatitis B nonresponders) show the strongest overpro-diabetic patients. However, due to the lower patient num-
ber per group in this analysis, no statistically significant duction of inflammatory cytokines [1]. Production of the
numerous pro-inflammatory cytokines is controlled bydifferences could be found (data not shown).
the regulatory cytokine IL-10 [23]. This substance is in-
Impact of the IL-10 genotype on the cytokine duced in the same cell types and by the same stimuli as
pattern in vitro the pro-inflammatory mediators and follows their initial
secretion with a delay of 8 to 12 hours [14, 24]. IL-10The1082 G* allele has been associated with a higher
seems to be the physiological mechanism to shut downproduction of the IL-10 protein than the1082 A* allele
inflammatory responses after a pathogen has been elimi-in healthy persons [15]. To show that this association
nated. In a mouse model, disruption of the IL-10 genealso is present in hemodialysis patients the PBMC from
leads to a chronic inflammatory state [25]. We could showpatients homozygous for the 1082 G* allele or the
earlier that the inflammation-limiting effect of IL-10 is1082 A* allele were stimulated with either LPS to
functional in hemodialysis patients; however, higher lev-detect monocyte derived cytokines or with PHA or anti-
els of the cytokine are needed to down-regulate the over-CD3 to detect mainly lymphocyte-derived cytokines.
production of IL-6 due to uremia and dialysis [1]. Indeed,Figure 1 shows that upon induction by LPS the produc-
there is an elevated production of IL-10 in hemodialysistion of IL-10 is higher in the patients with 1082 G*
patients [1, 26, 27], although not all patients achievethan in those with 1082 A*. In contrast, there was no
sufficient levels of the cytokine to control the chronicdifference between the amount of IL-10 upon activation
systemic inflammation. The reason for this heterogeneitywith both types of T-cell directed stimuli.
has not been clarified until now.The IL-10 genotype seems to have an indirect impact
The large interindividual variability in cytokine secre-on proinflammatory cytokines as well. We tested IL-6
tion upon a definite stimulus is determined, at least inas an example of monocyte-derived proinflammatory
part, by polymorphisms in the cytokine genes. This hasfactors that are physiologically controlled by IL-10. Fig-
been shown for several cytokines, among them IL-10ure 2 shows that there is much more variability in the
[15]. Three polymorphic loci in the promoter sequenceproduction of IL-6 in patients with an IL-10 1082 A*
of the human IL-10 gene have been localized. At positiongenotype than in IL-10 “high-producers” (1082 G*).
1082 upstream of the coding sequence either G or ADespite this tendency toward higher values in the pa-
is observed. Independently, at position 819 the basestients with IL-10 “low-producer” genotype, the produc-
T or C are found, which are linked to the bases A or Ction of IL-6 was not significantly different between both
at position 592 [15, 17]. PBMC from healthy personsgroups (P  0.07).
with G at1082 secrete higher levels of the IL-10 protein
upon stimulation by ConA than PBMC from donors with
DISCUSSION 1082 A* [15]. Although the quantitative differences in
Production of abnormally high levels of pro-inflam- cytokine secretion in vitro are within the range of 50%,
matory cytokines such as IL-1, IL-6 or TNF- by PBMC there is evidence that these differences are clinically rele-
is a well known finding in hemodialysis patients and has vant. The IL-10 genotype is predictive for the risk of auto-
immune diseases, which was most convincingly shown forbeen analyzed by several groups in recent years [1, 8,
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Fig. 1. Secretion of interleukin-10 (IL-10) by peripheral blood mononuclear cells (PBMC) from dialysis patients with different IL-10 genotypes
after incubation without stimuli (A) or with monocyte directed (LPS, B) or lymphocyte directed (PHA, C, or anti-CD3, D) stimuli. Only results
for stimulation by LPS were significantly different between both groups (P  0.05).
between the IL-10 genotype and the probability of a dial-
ysis patient to respond to a hepatitis B vaccination. The
1082 G* allele, which has been associated with high
production of IL-10, is found more frequently in patients
with a better immune function. There is a 39% higher
risk of severe immune dysfunction in patients homozygous
for 1082 A*. This finding further supports the role of
IL-10 in the pathogenesis of immune dysfunction in hemo-
dialysis patients. The effect of IL-10 in securing immune
function against the influences of uremia and dialysis could
be twofold: on the one hand, IL-10 promotes the function
of the humoral immune response by supporting the func-
Fig. 2. Production of IL-6 by PBMC from dialysis patients with differ- tion of B-cells [14]. By this mechanism patients with the
ent IL-10 genotypes after stimulation with LPS. The results were not high-producer genotype for IL-10 may more easily gener-
significantly different (P  0.07).
ate antibodies against the hepatitis B vaccine. On the
other hand, one of the main functions of IL-10 is the
inhibition of pro-inflammatory cytokines. This mechanism
chronic inflammatory bowel disease [28]. The IL-10 geno- seems at least to contribute to the impact on vaccination
type also influences the rate of acute rejection episodes response.
after kidney transplantation [29], although this effect de- Peripheral blood mononuclear cells from hemodialysis
pended on the TNF- genotype as well. patients with the 1082 G* allele produce more IL-10
upon monocyte directed stimulation by LPS than PBMCOur current study shows that there is an association
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